Supernus Pharmaceuticals (SUPN) Operating Expenses (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Operating Expenses data on file, last reported at $215.5 million in Q4 2025.

• Operating Expenses for Q4 2025 came in at $215.5 million, up 41.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $621.2 million (up 4.67% YoY), and the FY2025 annual result was $781.2 million, up 34.66% from the prior year.
• Operating Expenses fell to $215.5 million in Q4 2025 per SUPN's latest filing, from $252.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $252.3 million in Q3 2025 and troughed at $107.2 million in Q2 2021.
• A 5-year average of $154.5 million and a median of $151.6 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses fell 18.52% in 2023, then surged 87.13% in 2025.
• A 5-year view of Operating Expenses shows it stood at $153.0 million in 2021, then retreated by 13.05% to $133.0 million in 2022, then increased by 24.3% to $165.3 million in 2023, then slipped by 7.6% to $152.8 million in 2024, then surged by 41.08% to $215.5 million in 2025.
• Business Quant data shows SUPN's Operating Expenses at $215.5 million in Q4 2025, $252.3 million in Q3 2025, and $153.3 million in Q2 2025.